GSK and CureVac collaborate on vaccine and monoclonal antibody research programmes
London: GlaxoSmithKline (GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA…